Press Releases and Statements

CHPA commends the U.S. House of Representatives for swift passage of the Microbead-Free Waters Act of 2015 (H.R. 1321).

CHPA President and CEO Scott Melville released the following statement today regarding this afternoon’s House Energy and Commerce (E&C) Committee passage of the Microbead-Free Waters Act of 2015.

New members of the Consumer Healthcare Products Association (CHPA) Board of Directors were elected at the association’s board of directors meeting, held November 17 in Washington, D.C.

CHPA expresses its gratitude to New Jersey's governor, senator, and assembly members for shepherding the bill through the legislature. CHPA has long supported state efforts to curb teen OTC cough medicine abuse.

CHPA released the following statement in response to an article in Pediatrics, the official journal of the American Academy of Pediatrics, which reported a decline in emergency department visits for unsupervised medication exposures in young children.

CHPA is pleased to lend its strong support for the DXM Abuse Prevention Act of 2015 (H.R. 3250), introduced into the U.S. House of Representatives by U.S. Reps. Bill Johnson (R-OH) and Doris Matsui (D-CA).

CHPA highlights the results of a recent five-state survey from the Asthma and Allergy Foundation of America, which found that consumers on the whole, prefer full access to OTC medicine containing pseudoephedrine.

The Consumer Healthcare Products Association today issued the following statement in response to the Food and Drug Administration’s Drug Safety Communication on non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs).

CHPA applauds the Energy and Commerce Committee on House passage of the 21st Century Cures initiative. CHPA looks forward to the implementation of these provisions and believes it will help accelerate the discovery, development, and delivery of new treatments and cures for patients

CHPA released the following statement in support of today’s enactment of a Washington State law prohibiting the sale of OTC medicines containing the cough suppressant dextromethorphan (DXM) to minors.